Hepatocellular Carcinoma
Pipeline by Development Stage
Drug Modality Breakdown
Hepatocellular Carcinoma is a $2.2B market in peak growth phase, dominated by tyrosine kinase inhibitors and emerging immunotherapy combinations.
Key Trends
- Lenvatinib (LENVIMA) dominates with $779M spend; represents 35% of indication-specific market
- Shift from single-agent TKIs to immunotherapy combinations (anti-PD-1/CTLA-4 approaches gaining traction)
- Limited patent cliff risk; NEXAVAR LOE 2028 represents only $8M at-risk revenue
Career Verdict
Strong career opportunity for oncology specialists seeking high-value market with sustained clinical need and multiple career pathways across commercial, clinical operations, and medical affairs.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | LENVIMA (lenvatinib) | Eisai | $779M | 35% | Peak | Growing | 12.5yr |
| 2 | CABOMETYX (cabozantinib) | Exelixis | $1.1B | 50% | Peak | Growing | 7.2yr |
| 3 | STIVARGA (regorafenib) | Bayer | $111M | 5% | Peak | Stable | 6.2yr |
| 4 | FOTIVDA (tivozanib) | $102M | 5% | Peak | Stable | 13.5yr | |
| 5 | NEXAVAR (sorafenib) | Bayer | $8M | 0.4% | LOE_Approaching | Declining | 2.3yr |
Drug Class Breakdown
market consolidation around cabozantinib
lenvatinib maintains strong position
niche but stable segment
emerging combination segment with growth potential
includes pre-launch TACE candidates
Career Outlook
GrowingHCC represents a stable, maturing oncology indication with sustained clinical need and durable market economics ($2.2B market, 573 active trials). The market is dominated by two major commercial players (Eisai/LENVIMA, Exelixis/CABOMETYX) with limited disruption risk from patent cliffs, creating predictable career stability for established oncology professionals. Emerging immunotherapy combinations offer long-term innovation signals for those seeking pipeline exposure, while Commercial and Medical Affairs roles offer immediate opportunity across tier-1 oncology franchises.
Breaking In
Enter as Clinical Operations Coordinator or Commercial Associate within a tier-1 oncology company (AstraZeneca, Roche, BMS, Eisai) to build oncology-specific expertise and trial management credentials; HCC provides a smaller, less competitive entry point than lung/breast cancer franchises.
For Experienced Professionals
Experienced oncology professionals should target Medical Affairs or MSL roles at Eisai (LENVIMA lead) or Exelixis (CABOMETYX lead) to leverage established franchises; alternatively, pursue pipeline-focused roles to position for immunotherapy combination wave expected in Phase 3 by 2026-2027.
In-Demand Skills
Best For
Hiring Landscape
HCC-focused hiring ecosystem is fragmented across 11 companies with limited dedicated HCC-specific headcount; however, oncology portfolio hiring remains strong across major players (AstraZeneca 1,373 jobs, Roche 1,034 jobs, Amgen 1,228 jobs). Commercial roles dominate (1,801 positions) followed by Engineering (547), Manufacturing (462), and Clinical Operations (407). Top hiring companies include Abbott (1,408), J&J (1,373), AbbVie (1,051), and AstraZeneca (1,029) but data reflects broader pharma hiring, not HCC-specific positions.
Top Hiring Companies
By Department
Strong hiring across large-cap oncology players creates stable mid-to-senior level opportunities in Commercial (avg $225K), Clinical Operations (avg $307K), and Medical Affairs (avg $302K), though HCC-specific roles are embedded within broader oncology teams.
On Market (5)
Approved therapies currently available
Competitive Landscape
109 companies ranked by most advanced pipeline stage
+79 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 15,985 patients across 50 trials
The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction
Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
HepATocellular Cancer Hcv Therapy Study
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus
A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC
Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)
Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma
The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma
A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma
Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
Related Jobs in Oncology
Senior IT Infrastructure Engineer
Clinical Data Associate
Vice President and Head of Business Development
Associate Scientist (BS/MS) contractor – Lentiviral Vector Research & Early Process Development (100% Bench)
Medical Director, Early-Stage Clinical Development
Business Director Oncology BENELUX
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.